

SeQuent–Viyash merger receives stock exchange approvals

29 May 2025 | News

Laying the foundation for the next phase of growth



Sequent Scientific (SeQuent), a Mumbai-based player in the global animal health industry, has secured approvals from both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) for its proposed merger with Hyderabad-based Viyash Life Sciences (Viyash). The company has now filed for clearance with the National Company Law Tribunal (NCLT), marking a crucial milestone in the merger process.

The merger will bring together two strong business verticals—Global Animal Health and a world class integrated API business unlocking access to over 150 countries. The combined entity will benefit from a five-fold increase in R&D talent and a nine-fold expansion in USFDA-approved manufacturing capacity, creating a robust and scalable operating backbone.

US-based private equity firm Carlyle holds a 53% stake in SeQuent and is the majority shareholder in privately held Viyash. SeQuent operates in the niche segment of Animal Health and markets its products in 90+ countries. It has built local footprints in Europe, Latin America and emerging markets including India, while Viyash has built a strong presence in API and R&D space with strong business relations with leading companies around the globe.

Rajaram Narayanan, Managing Director of SeQuent Scientific, said, “This merger will accelerate a compelling new journey for SeQuent as a leading player in animal health, and Viyash with its world-class R&D capabilities and USFDA-approved facilities. FY 2024–25 marks a pivotal year for us, with strong business results as we accelerate our growth and lay the foundation for the next phase of growth. With Viyash joining us, we are poised to become a significantly stronger

business—2X in scale, capability, and opportunity.”

SeQuent reported a strong Q4 FY25 performance, with revenue rising 11.2% year-on-year to Rs 4,017 million and adjusted EBITDA increasing by 38.7% to Rs 569 million. Adjusted EBITDA margins expanded by 280 basis points to 14.2%, driven by an improved product mix, new launches and operational efficiencies.

In Q4 FY25, the combined entity of SeQuent and Viyash delivered robust performance with consolidated revenues of Rs 7,725 million, reflecting a 13.2% year-on-year growth.

Under the agreed terms, shareholders of Viyash will receive 56 SeQuent shares for every 100 Viyash shares held.